顺铂
染色质
DNA损伤
生物
衰老
癌变
组蛋白
癌症研究
DNA甲基化
表观遗传学
组蛋白H4
DNA修复
甲基转移酶
克隆形成试验
细胞生物学
癌症
甲基化
DNA
基因
细胞凋亡
遗传学
基因表达
化疗
作者
Daniele Musiani,Roberto Giambruno,Enrico Massignani,Marica Rosaria Ippolito,Marianna Maniaci,Sriganesh Jammula,Daria Manganaro,Alessandro Cuomo,Luciano Nicosia,Diego Pasini,Tiziana Bonaldi
出处
期刊:Cell Reports
[Cell Press]
日期:2020-01-01
卷期号:30 (4): 1208-1222.e9
被引量:53
标识
DOI:10.1016/j.celrep.2019.12.061
摘要
Protein arginine methyltransferase 1 (PRMT1) is overexpressed in various human cancers and linked to poor response to chemotherapy. Various PRMT1 inhibitors are currently under development; yet, we do not fully understand the mechanisms underpinning PRMT1 involvement in tumorigenesis and chemoresistance. Using mass spectrometry-based proteomics, we identified PRMT1 as regulator of arginine methylation in ovarian cancer cells treated with cisplatin. We showed that DNA-dependent protein kinase (DNA-PK) binds to and phosphorylates PRMT1 in response to cisplatin, inducing its chromatin recruitment and redirecting its enzymatic activity toward Arg3 of histone H4 (H4R3). On chromatin, the DNA-PK/PRMT1 axis induces senescence-associated secretory phenotype through H4R3me2a deposition at pro-inflammatory gene promoters. Finally, PRMT1 inhibition reduces the clonogenic growth of cancer cells exposed to low doses of cisplatin, sensitizing them to apoptosis. While unravelling the role of PRMT1 in response to genotoxic agents, our findings indicate the possibility of targeting PRMT1 to overcome chemoresistance in cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI